Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FEMY Femasys	$0.36 -0.4%	$0.81	$0.31 ▼ $1.80	$11.57M	-2.58	1.33 million shs	988,593 shs
NUWE Nuwellis	$5.10 -1.5%	$8.51	$4.82 ▼ $175.98	$4.60M	N/A	226,489 shs	21,971 shs
NVNO enVVeno Medical	$0.80 -8.1%	$3.95	$0.77 ▼ $5.70	$15.39M	1.01	1.88 million shs	2.07 million shs
NXGL NexGel	$2.45	$2.47	$2.10 ▼ $5.10	$19.81M	0.57	53,463 shs	28,676 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FEMY Femasys	0.00%	-37.81%	-57.18%	-59.65%	-66.18%
NUWE Nuwellis	0.00%	-2.30%	-46.88%	-86.07%	-90.51%
NVNO enVVeno Medical	0.00%	-20.06%	-82.66%	-77.79%	-84.95%
NXGL NexGel	0.00%	+5.60%	+8.89%	+11.87%	-13.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FEMY Femasys	3.0286 of 5 stars	3.5	3.0	3.0	2.5	0.6
NUWE Nuwellis	1.2237 of 5 stars	0.0	4.0	2.7	1.7	0.6
NVNO enVVeno Medical	0.5766 of 5 stars	0.0	2.0	2.0	0.8	1.3
NXGL NexGel	1.1651 of 5 stars	0.0	5.0	1.9	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FEMY Femasys	3.00	Buy	$7.33	1,965.15% Upside
NUWE Nuwellis	3.00	Buy	N/A	N/A
NVNO enVVeno Medical	2.00	Hold	N/A	N/A
NXGL NexGel	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NUWE, NXGL, NVNO, and FEMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	NVNO enVVeno Medical	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2025	FEMY Femasys	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $8.00
6/25/2025	FEMY Femasys	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
6/11/2025	FEMY Femasys	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00

(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FEMY Femasys	$1.63M	7.10	N/A	N/A	$0.05 per share	7.10
NUWE Nuwellis	$8.74M	0.53	N/A	N/A	($9.93) per share	-0.51
NVNO enVVeno Medical	N/A	N/A	N/A	N/A	$1.72 per share	N/A
NXGL NexGel	$8.69M	2.28	N/A	N/A	$0.63 per share	3.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FEMY Femasys	-$18.82M	-$0.86	N/A	N/A	N/A	-1,113.72%	-713.74%	-152.60%	11/11/2025 (Estimated)
NUWE Nuwellis	-$11.16M	-$35.36	N/A	N/A	N/A	-176.45%	-1,424.01%	-187.69%	11/10/2025 (Estimated)
NVNO enVVeno Medical	-$21.82M	-$1.20	N/A	N/A	N/A	N/A	-57.35%	-53.49%	10/29/2025 (Estimated)
NXGL NexGel	-$3.28M	-$0.40	N/A	∞	N/A	-25.02%	-49.37%	-25.68%	11/12/2025 (Estimated)

Latest NUWE, NXGL, NVNO, and FEMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	NUWE Nuwellis	-$0.45	-$60.99	-$60.54	-$60.99	$2.20 million	$1.73 million
8/12/2025	Q2 2025	NXGL NexGel	-$0.07	-$0.09	-$0.02	-$0.09	$3.08 million	$2.88 million
8/8/2025	Q2 2025	FEMY Femasys	-$0.18	-$0.16	+$0.02	-$0.16	$0.80 million	$0.41 million
7/31/2025	Q2 2025	NVNO enVVeno Medical	-$0.28	-$0.33	-$0.05	-$0.33	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FEMY Femasys	N/A	N/A	N/A	N/A	N/A
NUWE Nuwellis	N/A	N/A	N/A	N/A	N/A
NVNO enVVeno Medical	N/A	N/A	N/A	N/A	N/A
NXGL NexGel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FEMY Femasys	0.03	0.89	0.41
NUWE Nuwellis	N/A	2.16	1.64
NVNO enVVeno Medical	N/A	11.81	11.81
NXGL NexGel	0.16	1.74	0.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FEMY Femasys	65.27%
NUWE Nuwellis	3.13%
NVNO enVVeno Medical	34.71%
NXGL NexGel	2.21%

Insider Ownership

Company	Insider Ownership
FEMY Femasys	11.54%
NUWE Nuwellis	20.08%
NVNO enVVeno Medical	16.00%
NXGL NexGel	20.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FEMY Femasys	30	32.58 million	28.82 million	Not Optionable
NUWE Nuwellis	70	900,000	722,000	Not Optionable
NVNO enVVeno Medical	30	19.25 million	16.17 million	Optionable
NXGL NexGel	10	8.07 million	6.41 million	Not Optionable

NUWE, NXGL, NVNO, and FEMY Headlines

Recent News About These Companies

NEXGEL, Inc. (NASDAQ:NXGL) Just Reported Earnings, And Analysts Cut Their Target Price

August 16, 2025 | finance.yahoo.com

NEXGEL’s Earnings Call: Growth Amid Challenges

August 14, 2025 | msn.com

NexGel Inc Reports Strong Q2 2025 Revenue Growth

August 12, 2025 | msn.com

NEXGEL, Inc. (NXGL) Q2 2025 Earnings Call Transcript

August 12, 2025 | seekingalpha.com

NEXGEL Reports Second Quarter 2025 Financial Results

August 12, 2025 | taiwannews.com.twT

An Overview of NexGel's Earnings

August 11, 2025 | benzinga.com

NEXGEL Appoints Shutterstock Executive Steve Ciardiello to Board of Directors

August 7, 2025 | msn.com

NEXGEL to Report Second Quarter 2025 Financial Results on August 12th

August 6, 2025 | globenewswire.com

NexGel Inc Announces Direct Offering and Warrants Sale

August 2, 2025 | msn.com

NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Private Placement

August 1, 2025 | globenewswire.com

NEXGEL Expands Partnership With STADA, Secures $1 Million to Fuel New Product Launches

July 17, 2025 | msn.com

NEXGEL and STADA AG Announce Expansion of Partnership for North America

July 14, 2025 | globenewswire.com

NexGel Inc Stockholders Approve Key Proposals at Meeting

June 20, 2025 | tipranks.com

NEXGEL to Participate in the 6th Annual CEO Networking Event Hosted by Semco Capital on June 2nd

May 21, 2025 | finance.yahoo.com

Earnings call transcript: Nexgel’s Q1 2025 results show growth, future optimism

May 15, 2025 | uk.investing.com

NEXGEL, Inc. (NASDAQ:NXGL) Q1 2025 Earnings Call Transcript

May 15, 2025 | msn.com

NEXGEL, Inc. (NXGL) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

NEXGEL Reports First Quarter 2025 Financial Results

May 13, 2025 | taiwannews.com.twT

1NXGL : A Peek at NexGel's Future Earnings

May 12, 2025 | benzinga.com

NEXGEL to Announce Q1 2025 Financial Results on May 13

May 12, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUWE, NXGL, NVNO, and FEMY Company Descriptions

Femasys NASDAQ:FEMY

$0.36 0.00 (-0.45%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$0.36 +0.00 (+0.82%)

As of 08/29/2025 07:44 PM Eastern

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Nuwellis NASDAQ:NUWE

$5.10 -0.08 (-1.54%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$5.11 +0.01 (+0.10%)

As of 08/29/2025 06:37 PM Eastern

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

enVVeno Medical NASDAQ:NVNO

$0.80 -0.07 (-8.14%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$0.80 +0.01 (+0.70%)

As of 08/29/2025 07:31 PM Eastern

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

NexGel NASDAQ:NXGL

$2.45 0.00 (0.00%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$2.46 +0.00 (+0.20%)

As of 08/29/2025 04:10 PM Eastern

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time